- Home
- COYA vs MRSN Comparison
COYA vs MRSN Comparison
Compare COYA & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | MRSN |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 138.8M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | COYA | MRSN |
|---|---|---|
| Price | $5.25 | $29.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | $15.80 | ★ $30.38 |
| AVG Volume (30 Days) | ★ 225.7K | 114.7K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,987,706.00 | ★ $33,180,000.00 |
| Revenue This Year | $69.95 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.65 | $5.21 |
| 52 Week High | $8.29 | $36.25 |
Technical Indicators
Market Signals| Indicator | COYA | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 39.62 | 78.89 |
| Support Level | $5.29 | $28.11 |
| Resistance Level | $5.93 | $29.15 |
| Average True Range (ATR) | 0.40 | 0.57 |
| MACD | -0.01 | -0.47 |
| Stochastic Oscillator | 10.26 | 48.68 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.